Commodore Capital LP Has $61.22 Million Position in Alto Neuroscience, Inc. $ANRO

Commodore Capital LP boosted its position in Alto Neuroscience, Inc. (NYSE:ANRO) by 49.4% in the 1st quarter, HoldingsChannel.com reports. The firm owned 2,723,196 shares of the company’s stock after buying an additional 900,000 shares during the period. Alto Neuroscience comprises about 3.5% of Commodore Capital LP’s portfolio, making the stock its 11th biggest holding. Commodore Capital LP owned approximately 0.08% of Alto Neuroscience worth $61,217,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. AQR Capital Management LLC bought a new position in Alto Neuroscience during the 1st quarter worth $52,000. Torren Management LLC bought a new stake in shares of Alto Neuroscience in the fourth quarter valued at about $62,000. Invesco Ltd. bought a new stake in shares of Alto Neuroscience in the first quarter valued at about $67,000. Bridgeway Capital Management LLC boosted its position in shares of Alto Neuroscience by 85.9% in the second quarter. Bridgeway Capital Management LLC now owns 54,100 shares of the company’s stock valued at $119,000 after acquiring an additional 25,000 shares during the period. Finally, Balyasny Asset Management L.P. acquired a new position in shares of Alto Neuroscience in the fourth quarter valued at about $198,000.

Alto Neuroscience Stock Down 0.2%

ANRO stock opened at $26.72 on Monday. The company has a market cap of $937.53 million, a PE ratio of -11.04 and a beta of 1.04. The business has a 50-day simple moving average of $23.47 and a 200 day simple moving average of $21.53. Alto Neuroscience, Inc. has a 52 week low of $3.00 and a 52 week high of $28.85. The company has a quick ratio of 20.52, a current ratio of 20.52 and a debt-to-equity ratio of 0.07.

Alto Neuroscience (NYSE:ANRO) last posted its quarterly earnings data on Wednesday, May 13th. The company reported ($0.80) earnings per share for the quarter, missing the consensus estimate of ($0.56) by ($0.24). Sell-side analysts anticipate that Alto Neuroscience, Inc. will post -3.01 EPS for the current fiscal year.

Analysts Set New Price Targets

ANRO has been the topic of a number of recent research reports. JonesTrading lowered their price target on shares of Alto Neuroscience from $49.00 to $44.00 and set a “buy” rating on the stock in a research report on Thursday, April 2nd. Wall Street Zen upgraded shares of Alto Neuroscience from a “strong sell” rating to a “sell” rating in a research report on Saturday, July 18th. Wedbush raised their target price on shares of Alto Neuroscience from $21.00 to $24.00 and gave the stock a “neutral” rating in a report on Thursday, May 14th. Chardan Capital reaffirmed a “buy” rating and set a $30.00 target price on shares of Alto Neuroscience in a report on Wednesday, April 22nd. Finally, Weiss Ratings upgraded shares of Alto Neuroscience from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, May 1st. Eight equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $35.25.

About Alto Neuroscience

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.